You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDihydroetorphine
Accession NumberDB01450
TypeSmall Molecule
GroupsExperimental, Illicit
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQQX8S479YV
CAS number14357-76-7
WeightAverage: 413.5497
Monoisotopic: 413.256608613
Chemical FormulaC25H35NO4
InChI KeyInChIKey=BRTSNYPDACNMIP-FAWZKKEFSA-N
InChI
InChI=1S/C25H35NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,17-18,21,27-28H,5,8-14H2,1-4H3/t17-,18-,21-,22-,23-,24+,25-/m1/s1
IUPAC Name
(1S,2R,6S,14R,15R,16R)-16-[(2R)-2-hydroxypentan-2-yl]-15-methoxy-3-methyl-13-oxa-3-azahexacyclo[13.2.2.1²,⁸.0¹,⁶.0⁶,¹⁴.0⁷,¹²]icosa-7,9,11-trien-11-ol
SMILES
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)CCC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Azaspirodecane
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9829
Blood Brain Barrier+0.9712
Caco-2 permeable+0.7053
P-glycoprotein substrateSubstrate0.9173
P-glycoprotein inhibitor IInhibitor0.7031
P-glycoprotein inhibitor IINon-inhibitor0.8397
Renal organic cation transporterNon-inhibitor0.6108
CYP450 2C9 substrateNon-substrate0.8678
CYP450 2D6 substrateSubstrate0.7836
CYP450 3A4 substrateSubstrate0.8022
CYP450 1A2 substrateNon-inhibitor0.9409
CYP450 2C9 inhibitorNon-inhibitor0.8912
CYP450 2D6 inhibitorNon-inhibitor0.6514
CYP450 2C19 inhibitorNon-inhibitor0.8578
CYP450 3A4 inhibitorNon-inhibitor0.8133
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9418
Ames testNon AMES toxic0.7704
CarcinogenicityNon-carcinogens0.9335
BiodegradationNot ready biodegradable0.9958
Rat acute toxicity3.4494 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8552
hERG inhibition (predictor II)Non-inhibitor0.6577
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.114 mg/mLALOGPS
logP2.98ALOGPS
logP2.66ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)7.5ChemAxon
pKa (Strongest Basic)11.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.16 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity115.55 m3·mol-1ChemAxon
Polarizability46.49 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydroetorphine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Dihydroetorphine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the hypotensive activities of Dihydroetorphine.
AcepromazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydroetorphine.
adipiplonThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dihydroetorphine.
AlimemazineAlimemazine may increase the hypotensive activities of Dihydroetorphine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydroetorphine.
AlvimopanThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Dihydroetorphine which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydroetorphine.
AmoxapineDihydroetorphine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dihydroetorphine.
AmperozideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Dihydroetorphine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dihydroetorphine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydroetorphine.
ArticaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Asenapine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydroetorphine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dihydroetorphine.
AzaperoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Azaperone.
AzelastineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dihydroetorphine.
AzosemideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dihydroetorphine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dihydroetorphine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dihydroetorphine.
BenzphetamineBenzphetamine may increase the analgesic activities of Dihydroetorphine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Benzyl alcohol.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydroetorphine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.
BrimonidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydroetorphine.
BuprenorphineBuprenorphine may decrease the analgesic activities of Dihydroetorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydroetorphine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydroetorphine.
ButacaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dihydroetorphine.
ButorphanolButorphanol may decrease the analgesic activities of Dihydroetorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydroetorphine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dihydroetorphine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dihydroetorphine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydroetorphine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydroetorphine.
ChlorphentermineChlorphentermine may increase the analgesic activities of Dihydroetorphine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Dihydroetorphine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydroetorphine.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydroetorphine.
CitalopramDihydroetorphine may increase the serotonergic activities of Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with clomethiazole.
ClomipramineDihydroetorphine may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dihydroetorphine.
ClonazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydroetorphine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dihydroetorphine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dihydroetorphine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydroetorphine.
ConivaptanThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Conivaptan.
CyclizineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydroetorphine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dihydroetorphine.
CyclothiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydroetorphine.
DapoxetineDihydroetorphine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydroetorphine.
deramciclaneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydroetorphine.
DesipramineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dihydroetorphine.
DesmopressinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dihydroetorphine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydroetorphine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Dihydroetorphine.
DextromoramideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydroetorphine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dihydroetorphine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dihydroetorphine.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydroetorphine.
DifenoxinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dihydrocodeine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydroetorphine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydroetorphine.
DoramectinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.
DoxylamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Dihydroetorphine.
DrospirenoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydroetorphine.
EcgonineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Efonidipine.
EluxadolineDihydroetorphine may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dihydroetorphine.
EntacaponeThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Entacapone.
EplerenoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Eplerenone.
EscitalopramDihydroetorphine may increase the serotonergic activities of Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dihydroetorphine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydroetorphine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etacrynic acid.
EthanolDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dihydroetorphine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydroetorphine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dihydroetorphine.
EthosuximideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydroetorphine.
EtoperidoneDihydroetorphine may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fencamfamine.
FenfluramineDihydroetorphine may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydroetorphine.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydroetorphine.
FexofenadineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Flunitrazepam.
FluoxetineDihydroetorphine may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydroetorphine.
FluphenazineFluphenazine may increase the hypotensive activities of Dihydroetorphine.
FluphenazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydroetorphine.
FluspirileneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluticasone Propionate.
FluvoxamineDihydroetorphine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydroetorphine.
FosphenytoinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydroetorphine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dihydroetorphine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dihydroetorphine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dihydroetorphine.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dihydroetorphine.
GuanfacineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dihydroetorphine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dihydroetorphine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydroetorphine.
HeroinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dihydroetorphine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydroetorphine.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydroetorphine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dihydroetorphine.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydroetorphine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Dihydroetorphine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.
HydroxyzineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dihydroetorphine.
IloperidoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Imipramine.
IndalpineDihydroetorphine may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Indapamide.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydroetorphine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dihydroetorphine.
IsosorbideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Isosorbide.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydroetorphine.
KetazolamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ketobemidone.
KW-3902The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dihydroetorphine.
LevocabastineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydroetorphine.
LevomilnacipranDihydroetorphine may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydroetorphine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dihydroetorphine.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Dihydroetorphine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydroetorphine.
LofentanilThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydroetorphine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydroetorphine.
Lu AA21004Dihydroetorphine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Dihydroetorphine.
LurasidoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydroetorphine.
MeclizineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dihydroetorphine.
MelperoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Dihydroetorphine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydroetorphine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydroetorphine.
MersalylThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Dihydroetorphine.
MesoridazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dihydroetorphine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dihydroetorphine.
MethamphetamineMethamphetamine may increase the analgesic activities of Dihydroetorphine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dihydroetorphine.
MethapyrileneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydroetorphine.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Dihydroetorphine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydroetorphine.
MethsuximideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Dihydroetorphine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydroetorphine.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Dihydroetorphine.
MetolazoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metolazone.
MetyrosineDihydroetorphine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydroetorphine.
MilnacipranDihydroetorphine may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.
MirtazapineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dihydroetorphine.
MolindoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Dihydroetorphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydroetorphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Dihydroetorphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.
NabiloneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nabilone.
NalbuphineNalbuphine may decrease the analgesic activities of Dihydroetorphine.
NalbuphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Dihydroetorphine can be decreased when used in combination with Naltrexone.
NitrazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Dihydroetorphine.
OlanzapineDihydroetorphine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydroetorphine.
OlopatadineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydroetorphine.
OpiumThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Opium.
OrphenadrineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dihydroetorphine.
OsanetantThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydroetorphine.
OxprenololThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dihydroetorphine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydroetorphine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydroetorphine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydroetorphine.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dihydroetorphine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydroetorphine.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydroetorphine.
ParaldehydeDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dihydroetorphine.
ParoxetineDihydroetorphine may increase the serotonergic activities of Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydroetorphine.
PentazocinePentazocine may decrease the analgesic activities of Dihydroetorphine.
PentazocineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydroetorphine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dihydroetorphine.
PerampanelThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Dihydroetorphine.
PerphenazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydroetorphine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydroetorphine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Dihydroetorphine.
PhenytoinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydroetorphine.
PipamperoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydroetorphine.
PipotiazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydroetorphine.
PiretanideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pomalidomide.
PotassiumThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Potassium Citrate.
PramipexoleDihydroetorphine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dihydroetorphine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dihydroetorphine.
PrimidoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dihydroetorphine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Dihydroetorphine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydroetorphine.
PromazinePromazine may increase the hypotensive activities of Dihydroetorphine.
PromazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Dihydroetorphine.
PromethazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dihydroetorphine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydroetorphine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydroetorphine.
PropoxycaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydroetorphine.
QuinethazoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dihydroetorphine.
RamelteonThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ramelteon.
RamosetronDihydroetorphine may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydroetorphine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydroetorphine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydroetorphine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydroetorphine.
RomifidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Romifidine.
RopiniroleDihydroetorphine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydroetorphine.
RotigotineDihydroetorphine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dihydroetorphine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydroetorphine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydroetorphine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydroetorphine.
SertindoleThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Sertindole.
SertralineDihydroetorphine may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydroetorphine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dihydroetorphine.
SpironolactoneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Dihydroetorphine.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydroetorphine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydroetorphine.
SuvorexantThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydroetorphine.
TetrabenazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetrodotoxin.
ThalidomideDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dihydroetorphine.
TheobromineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydroetorphine.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Dihydroetorphine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydroetorphine.
ThioridazineThioridazine may increase the hypotensive activities of Dihydroetorphine.
ThioridazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tiagabine.
TicrynafenThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dihydroetorphine.
TizanidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydroetorphine.
TolvaptanThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydroetorphine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydroetorphine.
TrazodoneDihydroetorphine may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydroetorphine.
TriamtereneThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydroetorphine.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Dihydroetorphine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Dihydroetorphine.
TriflupromazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dihydroetorphine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydroetorphine.
TrimipramineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dihydroetorphine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dihydroetorphine.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydroetorphine.
UlaritideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Dihydroetorphine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dihydroetorphine.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydroetorphine.
VigabatrinThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Vigabatrin.
VilazodoneDihydroetorphine may increase the serotonergic activities of Vilazodone.
VortioxetineDihydroetorphine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dihydroetorphine.
XylazineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydroetorphine.
ZiconotideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ziconotide.
ZimelidineDihydroetorphine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydroetorphine.
ZolazepamThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dihydroetorphine.
ZonisamideThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dihydroetorphine.
ZotepineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Zuclopenthixol.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:09 / Updated on August 17, 2016 12:23